Neogen Corporation (NEOG) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed.
Is Neogen Corporation stock overvalued or undervalued in 2026?
As of October 30, 2026, Neogen Corporation (NEOG) trades at $11.82 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Neogen Corporation
Market cap $3B · 52 weeks $5 – $14 (15 % below the high) · P/E no earnings · 2027 est. P/E 35.5× · Dividend none · Next earnings January 14, 2027 · expected EPS $0.07 · Closing price, Oct 30 · accounts published Oct 6.
- Valuation: EV/EBITDA 30.3× (no earnings).
- Business: ROIC −0 % (weak).
- Balance sheet: Net debt/EBITDA 3.6× (fragile).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 0 of 4 pass
- R&D / Revenue 2.1 %, fails.
- Gross margin 46.9 %, fails.
- ROIC −0.2 %, fails.
- Net debt / EBITDA 3.6×, fails.
Against its peers (reference peers) — Neogen Corporation: P/E —; EV/EBITDA 30.3×; ROIC -0.2 %; $2.6B. Balchem Corp (P/E 32.1×; EV/EBITDA 20.0×; ROIC 11.9 %; $5.4B), Elanco Animal Health Incorporated (P/E —; EV/EBITDA 19.3×; ROIC 3.9 %; $11.5B), Zoetis Inc. (P/E 13.1×; EV/EBITDA 10.2×; ROIC 21.6 %; $32.9B).
Profitability
| Return on Equity | -2.68% |
| Return on Invested Capital | -0.19% |
| Return on Assets | -1.70% |
| Gross Margin | 47.40% |
| Operating Margin | -0.83% |
| Net Margin | -6.35% |
Financial Health
| Debt / Equity | 0.37 |
| Current Ratio | 3.90 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.10 |
Price Performance
| 1 month | -2.72% |
| 3 months | +0.08% |
| Year-to-date | +69.10% |
| 1 year | +91.57% |
| 3 years | -25.28% |
| 5 years | -73.03% |
| 10 years | -40.27% |
Related companies: MRK · IDXX · BCPC · ZTS · ELAN
Explore sector: Healthcare · Medical - Devices
More sections of NEOG: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks